CG Oncology’s (CGON) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of CG Oncology (NASDAQ:CGON) in a research note published on Tuesday morning,Benzinga reports. They currently have a $75.00 price objective on the stock.

CGON has been the topic of a number of other research reports. Royal Bank of Canada reiterated an “outperform” rating and issued a $66.00 price target on shares of CG Oncology in a research note on Friday, December 6th. TD Cowen assumed coverage on CG Oncology in a research note on Tuesday, January 7th. They set a “buy” rating for the company. Finally, Morgan Stanley reissued an “overweight” rating and set a $55.00 price target on shares of CG Oncology in a research report on Friday, March 7th. Nine investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $63.88.

CG Oncology Trading Down 3.5 %

Shares of CG Oncology stock opened at $27.54 on Tuesday. The business’s fifty day moving average price is $28.07 and its 200 day moving average price is $32.01. CG Oncology has a twelve month low of $23.91 and a twelve month high of $46.99.

Insiders Place Their Bets

In related news, Director Leonard E. Post sold 1,000 shares of CG Oncology stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $29.66, for a total transaction of $29,660.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Institutional Investors Weigh In On CG Oncology

Institutional investors and hedge funds have recently modified their holdings of the stock. GF Fund Management CO. LTD. purchased a new position in CG Oncology during the 4th quarter valued at about $41,000. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of CG Oncology during the 4th quarter valued at $68,000. KLP Kapitalforvaltning AS acquired a new position in shares of CG Oncology in the fourth quarter worth $100,000. Federated Hermes Inc. purchased a new stake in shares of CG Oncology during the fourth quarter worth $172,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in CG Oncology during the third quarter valued at $241,000. 26.56% of the stock is owned by institutional investors and hedge funds.

CG Oncology Company Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.